Cargando…
Immune cell labelling and tracking: implications for adoptive cell transfer therapies
BACKGROUND: The understanding of the role of different immune cell subsets that infiltrate tumors can help researchers in developing new targeted immunotherapies to reactivate or reprogram them against cancer. In addition to conventional drugs, new cell-based therapies, like adoptive cell transfer,...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859135/ https://www.ncbi.nlm.nih.gov/pubmed/33537909 http://dx.doi.org/10.1186/s41181-020-00116-7 |
_version_ | 1783646667077058560 |
---|---|
author | Galli, Filippo Varani, Michela Lauri, Chiara Silveri, Guido Gentiloni Onofrio, Livia Signore, Alberto |
author_facet | Galli, Filippo Varani, Michela Lauri, Chiara Silveri, Guido Gentiloni Onofrio, Livia Signore, Alberto |
author_sort | Galli, Filippo |
collection | PubMed |
description | BACKGROUND: The understanding of the role of different immune cell subsets that infiltrate tumors can help researchers in developing new targeted immunotherapies to reactivate or reprogram them against cancer. In addition to conventional drugs, new cell-based therapies, like adoptive cell transfer, proved to be successful in humans. Indeed, after the approval of anti-CD19 CAR-T cell therapy, researchers are trying to extend this approach to other cancer or cell types. MAIN BODY: This review focuses on the different approaches to non-invasively monitor the biodistribution, trafficking and fate of immune therapeutic cells, evaluating their efficacy at preclinical and clinical stages. PubMed and Scopus databases were searched for published articles on the imaging of cell tracking in humans and preclinical models. CONCLUSION: Labelling specific immune cell subtypes with specific radiopharmaceuticals, contrast agents or optical probes can elucidate new biological mechanisms or predict therapeutic outcome of adoptive cell transfer therapies. To date, no technique is considered the gold standard to image immune cells in adoptive cell transfer therapies. |
format | Online Article Text |
id | pubmed-7859135 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-78591352021-02-16 Immune cell labelling and tracking: implications for adoptive cell transfer therapies Galli, Filippo Varani, Michela Lauri, Chiara Silveri, Guido Gentiloni Onofrio, Livia Signore, Alberto EJNMMI Radiopharm Chem Review BACKGROUND: The understanding of the role of different immune cell subsets that infiltrate tumors can help researchers in developing new targeted immunotherapies to reactivate or reprogram them against cancer. In addition to conventional drugs, new cell-based therapies, like adoptive cell transfer, proved to be successful in humans. Indeed, after the approval of anti-CD19 CAR-T cell therapy, researchers are trying to extend this approach to other cancer or cell types. MAIN BODY: This review focuses on the different approaches to non-invasively monitor the biodistribution, trafficking and fate of immune therapeutic cells, evaluating their efficacy at preclinical and clinical stages. PubMed and Scopus databases were searched for published articles on the imaging of cell tracking in humans and preclinical models. CONCLUSION: Labelling specific immune cell subtypes with specific radiopharmaceuticals, contrast agents or optical probes can elucidate new biological mechanisms or predict therapeutic outcome of adoptive cell transfer therapies. To date, no technique is considered the gold standard to image immune cells in adoptive cell transfer therapies. Springer International Publishing 2021-02-03 /pmc/articles/PMC7859135/ /pubmed/33537909 http://dx.doi.org/10.1186/s41181-020-00116-7 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Review Galli, Filippo Varani, Michela Lauri, Chiara Silveri, Guido Gentiloni Onofrio, Livia Signore, Alberto Immune cell labelling and tracking: implications for adoptive cell transfer therapies |
title | Immune cell labelling and tracking: implications for adoptive cell transfer therapies |
title_full | Immune cell labelling and tracking: implications for adoptive cell transfer therapies |
title_fullStr | Immune cell labelling and tracking: implications for adoptive cell transfer therapies |
title_full_unstemmed | Immune cell labelling and tracking: implications for adoptive cell transfer therapies |
title_short | Immune cell labelling and tracking: implications for adoptive cell transfer therapies |
title_sort | immune cell labelling and tracking: implications for adoptive cell transfer therapies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859135/ https://www.ncbi.nlm.nih.gov/pubmed/33537909 http://dx.doi.org/10.1186/s41181-020-00116-7 |
work_keys_str_mv | AT gallifilippo immunecelllabellingandtrackingimplicationsforadoptivecelltransfertherapies AT varanimichela immunecelllabellingandtrackingimplicationsforadoptivecelltransfertherapies AT laurichiara immunecelllabellingandtrackingimplicationsforadoptivecelltransfertherapies AT silveriguidogentiloni immunecelllabellingandtrackingimplicationsforadoptivecelltransfertherapies AT onofriolivia immunecelllabellingandtrackingimplicationsforadoptivecelltransfertherapies AT signorealberto immunecelllabellingandtrackingimplicationsforadoptivecelltransfertherapies |